Translational Theranostics in Glioblastoma: FAPI-46 as a Precision Medicine Tool
Journal of Nuclear Medicine · 2026
DOI: 10.2967/jnumed.125.271759 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2026. Verfasst von Pauline Jeanjean und 14 weiteren Autor:innen. Beteiligte Einrichtung: Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, C…. Hauptthemen laut MEDLINE: Glioblastoma, Precision Medicine, Gelatinases, Membrane Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Glioblastoma represents the most lethal form of brain cancer, characterized by a 5-y survival rate of approximately 4%. Fibroblast activation protein (FAP), expressed within both the tumor microenvironment and glioblastoma cells, has been identified as a promising therapeutic target. This study explores the potential of FAP-targeted molecular probes as theranostic agents for glioblastoma.
Methods
Human U-87 MG and murine SB28 glioblastoma-derived cell lines were used to establish immunodeficient and immunocompetent models, respectively. FAP inhibitor (FAPI)-46 was radiolabeled with 68Ga for imaging and 225Ac or 177Lu for therapy. Tumor uptake, therapeutic efficacy, immunomodulatory effects, and survival were evaluated for FAPI-46 alone or in combination with temozolomide in preclinical studies. [68Ga]Ga-FAPI-46 tumor uptake was also evaluated in patients.
Results
In subcutaneous xenografts, [68Ga]Ga-FAPI-46 exhibited high tumor uptake with minimal background signal. In the immunocompromised model, a single dose of [225Ac]Ac-FAPI-46 combined with temozolomide was sufficient to increase median survival, whereas in the immunocompetent model, 3 consecutive daily doses were required to achieve a significant survival benefit. [177Lu]Lu-FAPI-46 demonstrated lower therapeutic efficacy, as a monotherapy or in combination with temozolomide, than did [225Ac]Ac-FAPI-46. Immunomodulatory effects, assessed via flow cytometry, were insufficient to overcome the immunologically "cold" glioblastoma tumor microenvironment. In orthotopic xenografts and patients, [68Ga]Ga-FAPI-46 showed low uptake, indicating limited blood-brain barrier penetration and resulting in tumor concentrations likely too low for therapeutic efficacy.
Conclusion
FAPI-46 demonstrates significant potential as a theranostic agent for glioblastoma in peripheral models. However, its inability to cross the blood-brain barrier in orthotopic models highlights the need for future studies to improve its clinical applicability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
- Jonsson Comprehensive Cancer Center, UCLA Health, Los Angeles, California.
- Division of Surgical Oncology, Department of Surgery, UCLA, Los Angeles, California; and.
- Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California; cmona@mednet.ucla.edu elie@bessererlab.org.
- California NanoSystems Institute, UCLA, Los Angeles, California.
Zitieren
APA
Jeanjean, P., Swaidan, A., Tse, C., Kwock, S., Fajnorova, I., Dove, R., Azrour, I. C., Taylor, S., Comin-Anduix, B., Nathanson, D. A., Carlucci, G., Calais, J., Czernin, J., Besserer-Offroy, É., & Mona, C. E. (2026). Translational Theranostics in Glioblastoma: FAPI-46 as a Precision Medicine Tool. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.125.271759
Vancouver
Jeanjean P, Swaidan A, Tse C, Kwock S, Fajnorova I, Dove R, et al. Translational Theranostics in Glioblastoma: FAPI-46 as a Precision Medicine Tool. Journal of Nuclear Medicine. 2026. doi:10.2967/jnumed.125.271759
BibTeX
@article{Jeanjean2026,
author = {Jeanjean, Pauline and Swaidan, Abir and Tse, Christopher and Kwock, Samantha and Fajnorova, Iveta and Dove, Rachel and Azrour, Ines Camille and Taylor, Sarah and Comin-Anduix, Begonya and Nathanson, David A and Carlucci, Giuseppe and Calais, Jérémie and Czernin, Johannes and Besserer-Offroy, Élie and Mona, Christine E},
title = {Translational Theranostics in Glioblastoma: FAPI-46 as a Precision Medicine Tool},
journal = {Journal of Nuclear Medicine},
year = {2026},
doi = {10.2967/jnumed.125.271759}
}
EUVIMED